Best Life Sciences Companies in Cleveland, United States
The 101 best Life Sciences companies in Cleveland, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Athersys.
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Cleveland
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Athersys Stem Cell Therapy for the treatment of cardiovascular disease areas | $218M | 74 mo ago | 113 | 1995 | — | — | 209 patents Multipotent adult progenitor cell therapies for immunomodulation and tissue regeneration | — |
| 2 | SPR Developer of non-implant peripheral nerve stimulation systems for pain management | $180M | 14 mo ago | — | 2008 | Maria Bennett Founder & CEO | DrupalApple iCloud MailMariaDB+22 | — | 2 launchs · 1 award |
| 3 | SPR Therapeutics Peripheral nerve stimulation therapy for treating pain | $174M | 28 mo ago | 198 | 2010 | Maria E Bennett Founder & CEO | — | 220 patents Implantable neurostimulation systems for chronic pain and back pain relief | — |
| 4 | Juventas Therapeutics Developer of non-viral gene therapies to treat cardiovascular diseases that target natural repair pathways | $107M | 55 mo ago | 1 | 2007 | — | — | — | — |
| 5 | Within3 Provider of an online collaboration solutions | $103M | 68 mo ago | 196 196 → 120 (-39%) | 2006 | Lance Hill Founder & CEO | WordPressApple iCloud MailMySQL+24 | 13 patents Integrating and analyzing biomedical datasets with linked databases and image/social network analytics | — |
| 6 | Cleveland Diagnostics Developer of diagnostics technology to detect cancer in early stage 53Funding top 21%Moat top 31%Growth top 35%Tech top 39% All 8 signals ▾Fundingtop 21% Moattop 31% Growthtop 35% Techtop 39% Talentbottom 49% Globalbottom 37% Marketbottom 36% Newsbottom 22% Funding: Raised $96.8M across 5 rounds · 5 rounds over 11 yrs (0.5/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 53/100 | $97M | 8 mo ago | 40 | 2013 | Arnon Chait President And Ceo | Squarespace CommerceSquarespaceSentry+25 | — | 1 award |
| 7 | Centerline Biomedical Developer of surgical navigation and image guidance system for endovascular procedures | $64M | 14 mo ago | 43 | 2014 | — | WordPressMySQLPHP+19 | 49 patents AR‑assisted navigation and control for minimally invasive cardiovascular interventions | — |
| 8 | Diasome Developer of therapies for the treatment of diabetes and other metabolic conditions | $60M | 22 mo ago | 7 | 2005 | W Blair Geho Founder & Director | — | — | 1 launch |
| 9 | Thermalin Diabetes Fast-acting and long-acting insulin analogs for Diabetes management | $57M | 69 mo ago | 18 | 2007 | — | — | 12 patents Fast-acting insulin formulations and advanced infusion delivery systems for diabetes management | — |
| 10 | Complient Corp Provides AEDs and CPR equipment and training | $52M | 293 mo ago | — | 1997 | Devdatt Kurdikar CEO | — | — | — |
| 11 | Novelmed Pioneering antibody therapies for complement-mediated rare and common diseases | $31M | 60 mo ago | — | 2003 | Rekha Bansal CEO | — | — | — |
| 12 | MediView Digital medical image management tool for providers | $29M | 6 mo ago | 6 | 2017 | Adam Rakestraw Co-Founder | WordPressMySQLPHP+31 | 71 patents AR/VR imaging fusion for real-time cardiovascular intervention guidance and device deployment | 1 job opening · 1 partnership |
| 13 | NeuroTherapia Developing small molecule therapies for neuroinflammatory disorders like Alzheimer's disease | $22M | 22 mo ago | 6 | 2015 | Joseph Foss Founder & Chief Medical Officer | — | 3 patents Pharmaceutical formulations for treating cognitive impairment (neurotherapeutics). | — |
| 14 | DATATRAK Cloud-based clinical trial data management solutions for efficient research | $21M | 94 mo ago | 50 | 1991 | Jim Bob Ward President & CEO | — | 8 patents Enterprise data integration and unified data management platforms | — |
| 15 | Convelo Therapeutics Developer of stem cell based therapeutics for the treatment of neurological disorders | $21M | 42 mo ago | 17 | 2016 | — | — | — | — |
| 16 | Gliatech Therapeutics for CNS disorders and inflammatory diseases | $20M | 344 mo ago | — | 1987 | Steven Basta Ex-CEO and President | — | — | — |
| 17 | GL Neurotech Developer of bioinstrumentation products for physiological monitoring and therapy | $18M | 17 mo ago | 15 15 → 21 (+40%) | 2010 | Robert Schmidt Chairman and CEO | — | — | — |
| 18 | Aeromics Developing aquaporin inhibitors for life-threatening conditions like stroke, improving patient outcomes | $14M | 90 mo ago | 2 | 2006 | — | — | 104 patents Pharmaceutical solid forms and formulations of aquaporin‑inhibiting prodrugs for cerebral edema treatment | — |
| 19 | Complion Software solutions for clinical trial regulatory documentation. | $14M | 73 mo ago | 33 | 2012 | — | — | — | — |
| 20 | NeuroWave Systems Neurodiagnostic device and accessories | $13M | 83 mo ago | 15 | 2003 | — | Apache HTTP ServerStatcounterGoogle Analytics+2 | — | — |
| 21 | m2m Imaging Corp. Preclinical MRI Imaging Devices and Accessories | $13M | 209 mo ago | — | 2006 | Richard Hullihen CEO | — | 19 patents High‑field MRI RF coil design, cryogenic cooling, and bandwidth enhancement. | — |
| 22 | Lazurite Developer of arthroscopic surgical devices for treating joint problems | $13M | 17 mo ago | 17 17 → 34 (+100%) | 2015 | Eugene Malinskiy Co-Founder & CPTO | — | 41 patents Wireless medical imaging devices integrating advanced light sources, converters, and portable power solutions. | 1 job opening |
| 23 | ClotChip Innovative point-of-care blood coagulation diagnostics for accessible clinical evaluation | $9M | 95 mo ago | 5 | 2016 | — | — | — | — |
| 24 | Algisys Producer of algal-based EPA omega-3 oils and vegan protein | $9M | 154 mo ago | 7 | 2009 | Charles Roe Chief Technology Officer and Co-Founder | — | 11 patents Microbial production of omega‑3 fatty acids using Pythium fermentation processes. | — |
| 25 | BIOHM Provider of personalised nutraceutical supplements | $8M | 16 mo ago | 23 | 2016 | Afif Ghannoum Co-Founder & CEO | Cart FunctionalityShopifySentry+54 | — | — |
| 26 | BioInVision Biotech imaging solutions: CryoViz & IschemiaViz for preclinical and clinical applications | $7M | 13 mo ago | 11 | 2005 | — | — | — | — |
| 27 | Dual Therapeutics Develops small molecule therapeutics for prostate cancer, lung cancer, and acute lymphoblastic leukemia | $6M | 140 mo ago | 1,165 | 2013 | Michael Ohlmeyer Co-Founder | — | — | — |
| 28 | GenomOncology Developer of precision medicine by transforming genomic data into actionable information | $6M | 73 mo ago | 56 56 → 53 (-5%) | 2012 | — | — | 3 patents Computational analysis of genomic variants using discrete data structures for precision oncology | 1 job opening |
| 29 | Haima Therapeutics Developer of therapeutics for the treatment of bleeding and other ailments | $6M | 14 mo ago | 6 | 2016 | Christa Pawlowski Co-Founder | — | — | — |
| 30 | Peritec Biosciences Peripheral Vascular Stents | $5M | 164 mo ago | 1 | 2003 | Timur Paul Sarac Founder | — | — | — |
| 31 | Molecular Theranostics Developer of non-invasive imaging technologies for the detection of cancer | $5M | 23 mo ago | — | 2014 | Yajuan Li CEO | — | — | — |
| 32 | CollaMedix Developer of device for treating urinary incontinence in women | $4M | 33 mo ago | 8 | 2018 | Donna Richardson CEO | — | — | — |
| 33 | Sap Vax Developer of self-adjuvanting peptide vaccine immunotherapies for cancer | $3M | 89 mo ago | 4 | 2016 | Baiju Shah CEO | — | — | — |
| 34 | Mercury Biomed A company launching soon, offering updates via email subscription | $3M | 93 mo ago | 3 | 2015 | Brad Pulver Chief Executive Officer | — | — | — |
| 35 | Theravasc Online entertainment platform offering diverse betting and gaming experiences | $3M | 147 mo ago | 1 | 2009 | — | — | 36 patents Nitrite-based pharmaceutical compounds and delivery formulations for therapeutic applications | — |
| 36 | Western Oncolytics Immuno-oncolytic therapy for Cancer | $3M | 132 mo ago | 1 | 2013 | — | BootstrapHandlebarsBackbone.js+6 | — | — |
| 37 | Koutif Therapeutics Developing novel therapeutics targeting inflammatory diseases through unique ubiquitin degradation pathway… | $3M | 92 mo ago | 6 | 2017 | — | — | — | — |
| 38 | Akrotome Molecular imaging tech revolutionizing cancer surgery with high-resolution probes | $2M | 45 mo ago | 2 | 2008 | Brian Straight President and CEO | — | — | — |
| 39 | NDI Medical Neurodevice venture capital firm developing innovative technologies for neurological function restoration | $2M | 190 mo ago | 110 | 2002 | Geoffrey Thrope Co-Founder & CEO | — | — | — |
| 40 | Synapse Biomedical Neurostimulation solutions improving lives of patients with spinal cord injuries and ALS | $2M | 150 mo ago | 27 | 2002 | — | Cart FunctionalityWordPressMySQL+24 | 32 patents Neuromodulation devices and methods for respiratory and neuromuscular therapy | — |
| 41 | ReXceptor Developing small molecules targeting retinoid X receptor to treat Alzheimer's | $2M | 141 mo ago | — | 2011 | Paige Cramer Co-Founder | — | — | — |
| 42 | Allinaire Therapeutics Developing novel therapeutics for cardiopulmonary diseases, including PAH and COPD | $2M | 4 mo ago | 4 | 2016 | — | — | — | — |
| 43 | RSB Spine Spinal fusion products for degenerative disc disease | $2M | 188 mo ago | — | 2001 | John Redmond CEO | — | 55 patents Spinal fixation plates and related orthopedic implant systems for vertebral stabilization | — |
| 44 | Cell X Technologies Developer of regenerative medicine to measure and manage human cell sources | $1M | 81 mo ago | 9 | 2017 | George Muschler Founder & CSO | WordPressMySQLPHP+21 | 70 patents CAR-engineered natural killer cell immunotherapies targeting HER2, CD20, EGFR, CD19 | — |
| 45 | Quality Electrodynamics MRI radiofrequency coil innovator revolutionizing medical imaging with advanced technology | $974K | 207 mo ago | 142 | 2006 | Hiroyuki Fujita Founder & CEO | WordPressMySQLPHP+22 | 100 patents Patents concentrated in computing, sensing & instrumentation | — |
| 46 | Sujana Biotech US-based, early-stage biotech developing MAbs and Small Molecule therapeutics for inflammatory and vascular… | $800K | 121 mo ago | — | 2015 | Baiju Shah CEO | — | — | — |
| 47 | JanusQ Developer of peptide-based therapeutics for neurological disorders | $760K | 17 mo ago | — | 2020 | George Farr CEO | — | — | — |
| 48 | Abcon Therapeutics Developer of antibody-drug conjugates for T-cell lymphoma treatment | $658K | 45 mo ago | — | 2019 | David Fox Co-Founder | — | — | — |
| 49 | AxoNeural Therapeutics Developer of nanoparticle-based therapeutics for neurodegenerative injuries | $400K | 60 mo ago | — | 2020 | Vinod Labhasetwar Founder & CSO | — | — | — |
| 50 | Deep Brain Innvovations Deep brain stimulation technology | $393K | 84 mo ago | — | 2012 | Geoffrey Thrope CEO | — | — | — |
Top 12 Life Sciences companies in Cleveland
#1
Series E · Cleveland, Ohio · founded 2013 · 40 employees$96.8Mraised▾
ClevelandDx has developed diagnostics technology to detect cancer in early-stage. The company uses specific biomarkers to distinguish the non-cancerous and cancerous conditions. The expression of these biomarkers is based on a proprietary technology that separates protein isoforms, based on structure.
- Oct 2025Series E$14.4M
- Jan 2024Series E$75M
- Feb 2021Series D$19.4M
- Nov 2016Conventional Debt—
#2
Series A · Cleveland, Ohio · founded 2017 · 6 employees$29.4Mraised▾
Digital medical image management tool for providers. The company has developed software like MediView XR30, MediView XR50, and MediView XR90. It has features for augmented reality visualization, remote collaboration, clinical image analysis, and democratizing and informing healthcare delivery.
- Nov 2025Series A$24M
- Oct 2025Series A$24M
- Dec 2024Series A$14M
- May 2023Series A$15M
#3
Acquired · Cleveland, Ohio · founded 2008$180.3Mraised▾
Developer of non-implant peripheral nerve stimulation systems for pain management. This company provides a clinically proven, patient-preferred non-surgical option for managing chronic, intractable, post-surgical, post-traumatic, and post-operative pain. The system offers symptomatic relief and is indicated for up to 60 days of use. The most common adverse events are skin irritation and erythema. The company is focused on advancing non-opioid, non-surgical, minimally invasive pain management solutions.
- Mar 2025Grant (prize money)$6M
- Feb 2024Convertible Debt$60M
- Jan 2024Series D$25.6M
- Oct 2021Series D$37M
#4
Series B · Cleveland, Ohio · founded 2014 · 43 employees$63.8Mraised▾
Developer of surgical navigation and image guidance system for endovascular procedures. The flagship product of the company is the Intra-Operative Positioning System (IOPS) based on 3D GPS-like surgical navigation technology for predictive modeling and clinical decision support. Also, it offers x-ray fluoroscopy for 2D image guidance.
- Apr 2025Series B$10.8M
- Feb 2025Grant (prize money)$1.3M
- Feb 2022Series B$34.7M
- May 2020Grant (prize money)$1.5M
#5
Seed · Cleveland, Ohio · founded 2016 · 4 employees$1.6Mraised▾
Developing novel therapeutics for cardiopulmonary diseases, including PAH and COPD. The company is focused on creating humanized anti-endothelial monocyte activating polypeptide II (EMAP II) monoclonal antibodies as a potential disease-modifying treatment. Their pioneering research highlights the pathogenic role of EMAP II in conditions like pulmonary arterial hypertension, chronic obstructive pulmonary disease, and viral-induced acute lung injury. The company leverages a network of preclinical and clinical scientists to advance its therapeutic pipeline. Their approach targets apoptosis, cell injury, endothelial cell function, and inflammation, aiming to provide innovative solutions for unmet medical needs in the cardiopulmonary space. The company is focused on research and development of novel treatments.
- Jan 2026Seed$700K
- Dec 2018Seed$1.6M
- Feb 2018Grant (prize money)$281.2K
- Jun 2017Grant (prize money)$211K
#6
Series C · Cleveland, Ohio · founded 2005 · 7 employees$59.7Mraised▾
Developer of therapies for the treatment of diabetes and other metabolic conditions. The company focuses on the development of Hepatocyte Directed Vesicles (HDV) liver targeted delivery system for insulin delivery to liver hepatocytes in order to significantly reduce the risk of hypoglycemia in patients with diabetes.
- Jul 2024Series C$3.1M
- Dec 2023Series C—
- Jun 2023Series B$9M
- Dec 2020Series B$1.5M
#7
Funding Raised · Cleveland, Ohio · founded 2010 · 15 employees$17.9Mraised▾
Developer of bioinstrumentation products for physiological monitoring and therapy. The products include physiological monitors and patient-centered diagnostic and therapy systems integrated with wireless, remote, and web-based applications. The companys offerings support research and education, focusing on movement disorders like parkinsons disease, telemedicine, and in-home health monitoring. Manufacturing, distribution, and export of research systems and medical devices are also core business activities.
- Jan 2025Grant (prize money)$1.7M
- Sep 2023Grant (prize money)$289.5K
- Sep 2018Grant (prize money)$1.7M
- Jul 2018Grant (prize money)$224.7K
#8
Funding Raised · Cleveland, Ohio · founded 2005 · 11 employees$7Mraised▾
Biotech imaging solutions: CryoViz & IschemiaViz for preclinical and clinical applications. They specialize in advanced imaging technologies and software for biotechnology problems. Their core competency lies in CryoViz imaging, offering high-resolution, large field-of-view microscopic imaging with 3D reconstruction and specialized image processing. This technology bridges the gap between in vivo imaging and histology, enabling detailed analysis from whole organisms to sub-cellular levels. Applications span stem cells, cancer research, molecular imaging, gene expression, toxicology, biomarker validation, and anatomical phenotyping. They also offer IschemiaViz, an AI-powered software for cardiac perfusion CT analysis, aiding cardiologists in diagnosing cardiovascular disease. They provide imaging services, analyzing samples and delivering results with sensitivity and precision. Their solutions cater to both preclinical and clinical markets, offering tools for cellular and molecular imaging, multi-spectral fluorescence, and automated 3D visualization.
- Apr 2025Grant (prize money)$224.2K
- Aug 2022Grant (prize money)$224.2K
- Aug 2021Grant (prize money)$1M
- Aug 2018Grant (prize money)$224.2K
#9
Series A · Cleveland, Ohio · founded 2016 · 23 employees$8.5Mraised▾
Provider of personalised nutraceutical supplements. It offers supplements based on quiz for gut assesment which includes probiotics and super blends to improve gut health, digestion, women health, and boosts immune system.
- Feb 2025Series A$1.5M
- Dec 2024Series A$3M
- Nov 2023Series A$1M
- Jan 2023Series A$7.5M
#10
Series A · Cleveland, Ohio · founded 2015 · 17 employees$12.9Mraised▾
Developer of arthroscopic surgical devices for treating joint problems. The company offers a modular ArthroFree wireless camera system for minimally invasive surgery. Also, provides Meridiem light engine for signal transmission, power, and light in ArthroFree.
- Dec 2024Series A$1.7M
- Jun 2021Series A$10M
- Sep 2015Seed$1.3M
#11
Funding Raised · Cleveland, Ohio · founded 2016 · 6 employees$5.7Mraised▾
Developer of therapeutics for the treatment of bleeding and other ailments. The company develops platelet-inspired therapeuticsto mitigate bleeding and treat other blood-related disorders such as thrombosis, inflammation, and cancer.
- Apr 2025Grant (prize money)$2.1M
- Apr 2020Grant (prize money)$949.2K
- Jun 2019Grant (prize money)$2.4M
- Jan 2018Grant (prize money)$225K
#12
Series B · Cleveland, Ohio · founded 2015 · 6 employees$22.1Mraised▾
Developing small molecule therapies for neuroinflammatory disorders like Alzheimer's disease. This clinical-stage company focuses on creating innovative treatments for central nervous system diseases by targeting neuroinflammation. Their approach involves oral, small molecule therapeutics that inhibit microglia cells, reducing inflammation in the CNS. The lead program, NTRX-07, aims to improve learning and memory by reducing inflammation and enhancing brain connectivity. This represents a novel approach, potentially working synergistically with existing antibody therapies. They are developing treatments for neuroinflammatory disorders such as neuropathic pain, multiple sclerosis and ALS. Their lead product is a highly selective cannabinoid receptor agonist with demonstrated CNS activity that targets receptors on microglia, which significantly reduces the expression of inflammatory agents resulting in neuronal survival and activation.
- Aug 2024Series B$12.3M
- Sep 2020Series A$8.8M
- Sep 2016Grant (prize money)$1.7M
- Oct 2015Seed$1M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
What Cleveland researches in biotechnology
Cleveland Clinic leads Cleveland's cautiously optimistic biotech research, focusing on IBD and lymphoma immunology using single-cell transcriptomics, with breakthroughs dominating but concerns present.
- Cleveland Clinic27
- Cleveland Clinic Lerner College of Medicine6
- Louis Stokes Cleveland VA Medical Center3
- Cleveland Foundation2
- University Hospitals of Cleveland1
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.